1981
DOI: 10.1111/j.1365-2141.1981.tb07251.x
|View full text |Cite
|
Sign up to set email alerts
|

Thymidine Kinase Isoenzymes in Chronic Lymphocytic Leukaemia

Abstract: The profile of thymidine kinase isoenzymes was determined in peripheral blood lymphocytes from 14 patients with chronic lymphocytic leukaemia (CLL) and 31 controls. Twelve patients with indolent disease showed TK2 isoenzyme activity, while two patients in whom the disease evolved and two patients who presented with aggressive disease exhibited TK1 isoenzyme activity. The demonstration of TK1 activity in the peripheral blood lymphocytes of clinically aggressive CLL suggests that this isoenzyme may be a useful b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
19
1

Year Published

1983
1983
2007
2007

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 36 publications
(20 citation statements)
references
References 5 publications
0
19
1
Order By: Relevance
“…123 I-ITdU is metabolically incorporated into DNA via the thymidine salvage pathway (7,8). This targeting approach seems promising because ENT1-type nucleoside transporters and key enzymes of the thymidine salvage pathway, major determinants of cellular 123 I-ITdU metabolism, are overexpressed in leukemic cells and many malignant tumors (23)(24)(25)(26)(27).…”
Section: Discussionmentioning
confidence: 99%
“…123 I-ITdU is metabolically incorporated into DNA via the thymidine salvage pathway (7,8). This targeting approach seems promising because ENT1-type nucleoside transporters and key enzymes of the thymidine salvage pathway, major determinants of cellular 123 I-ITdU metabolism, are overexpressed in leukemic cells and many malignant tumors (23)(24)(25)(26)(27).…”
Section: Discussionmentioning
confidence: 99%
“…Studies of 23 matched human neoplastic and normal tissue pairs showed higher dTk activity in tumours, except for bronchogenic carcinomas and hypernephromas (Gordon et al, 1968). Recent reports have demonstrated enhanced dTk-F levels in peripheral blood lymphocytes of some patients suffering from non-Hodgkin's lymphoma (NHL) or active chronic lymphocytic leukaemia (Ellims et al, 1981a;Ellims, 1981;Kreis et al, 1982). These investigators, although using an enzyme assay with radiolabelled dT as substrate, were able to find dTk-F in the serum of 26 patients with advanced NHL.…”
mentioning
confidence: 99%
“…For example, patients in early stage with heavy bone marrow infiltration or rapidly increasing blood lymphocyte counts are likely to have progressive disease, whereas those with nonmassive bone marrow involvement and low, stable blood lymphocyte levels of the disease tend to have an indolent and nonprogressive (smoldering) disease [63]. A similar discriminant power has been claimed for thymidin-kinase, LDH, CD23, ICAM-1, and P-2-microglobulin serum levels [64][65][66][67], although the prognostic value of these markers should be studied further. It is possible that in the future a clinicobiological system (i.e., a system combining clinical and biological parameters) can replace the current staging systems based on clinical and routine analytical data.…”
Section: When To Treatmentioning
confidence: 71%